Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Actuate Therapeutics, Inc. (NASDAQ: ACTU) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission documents, along with AI-powered tools to help interpret complex regulatory disclosures. As a clinical-stage biopharmaceutical company and emerging growth company, Actuate uses SEC filings to describe its oncology pipeline, capital-raising activities, and key risks associated with developing elraglusib, its lead GSK-3β inhibitor.
Investors can review current and periodic reports, including Forms 8-K that detail material events. For example, Actuate has filed 8-Ks describing a June 2025 securities purchase agreement for a private placement of common stock and warrants, a registration rights agreement for those securities, and a September 2025 underwriting agreement for a public offering of common stock under an effective Form S-3 shelf registration statement. Another 8-K outlines the company’s use of its website, SEC filings, press releases, and social media accounts as disclosure channels.
Registration statements such as the Form S-1 filed in July 2025 provide additional background on Actuate’s business. In that document, the company explains that it is a clinical-stage biopharmaceutical company focused on high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3, and describes elraglusib as an ATP-competitive small molecule designed to block GSK-3β and affect tumor survival and anti-tumor immunity.
On Stock Titan, users can access these filings as they are made available through EDGAR and use AI-generated summaries to quickly identify key points, such as financing terms, development strategy, and risk factor themes. The filings page is also a starting point for tracking future annual reports on Form 10-K, quarterly reports on Form 10-Q, and beneficial ownership or insider transaction reports on Form 4 when they are filed, helping investors build a more complete picture of ACTU’s regulatory and financial profile.
Actuate Therapeutics (NASDAQ:ACTU) entered a $4.7 million private placement with institutional and accredited investors, selling 666,497 common shares at $7.00 and issuing 666,497 cash-only warrants at the same price. Warrants are immediately exercisable and expire 20 days after an FDA milestone (Breakthrough Therapy designation or Phase 2/3 registration pathway feedback), potentially providing another $4.7 million.
Closing is expected by June 30 2025; proceeds earmarked for working capital. Bios 2024 Co-Invest will hold ~49.9 % beneficial ownership post-deal. A Registration Rights Agreement requires ACTU to file a resale shelf by August 9 2025 and meet strict effectiveness deadlines, with liquidated damages for failure.
- Item 1.01: Securities Purchase & Warrants
- Item 3.02: Unregistered sales under Reg D
- Going-concern risk remains despite new funding.